Non-Hodgkin's lymphoma refractory

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
1 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase I/II: 1 Phase I: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase I/II

1 trial

Phase I

1 trial
  • Celgene Corp. Commercial
    IMP not specified
    2023-509969-20-00 2 countries 2017 n=127
    Ended

Phase I (Other)

1 trial
  • Novartis Pharma AG Commercial
    IMP not specified
    2024-511489-35-00 3 countries 2022 n=30
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase I 0
Novartis Pharma AG Commercial 1 Phase I (Other) 0
Innate Pharma Commercial 1 Phase I/II 0
New trials by year
2022
1
2024
1
← All indication landscapes